#Paris #France #Cancer Research #Okomera #Silvère Lucquin

Okomera Welcomes New CEO Silvère Lucquin

On September 8, 2025, Okomera, a Paris-based startup advancing oncology research, announced the appointment of Silvère Lucquin as its Chief Executive Officer. Lucquin takes the reins from Sidarth Radjou, who has opted to pursue new professional opportunities after leading the company through a significant phase of its growth.

Silvère Lucquin, who boasts over a decade of expertise in the Medtech and Life Science sectors, steps into this crucial role with a commendable track record. His prior role as Chief Operating Officer at Ganymed Robotics showcased his ability to drive company strategy and promote rapid expansion within the industry. Lucquin also played a pivotal role in human resources, business modeling, industrial partnerships, and product development.

Before his tenure at Ganymed, he held crucial positions at Aditlys Medical, overseeing the company's spin-off and initial structuring processes. At CorWave, where he served as the first employee, he was integral in driving major development activities, contributing to the company's growth during two significant fundraising rounds—Series A and B.

An engineer by training, Lucquin completed his studies at École Polytechnique in France and Imperial College London, also earning an MBA from INSEAD. This combination of technical knowledge and business acumen equips him with a unique perspective necessary to lead Okomera as it seeks to expand its impact on cancer research amid rapidly evolving technological landscapes.

Richard Eglen, Chair of the Okomera Board, expressed excitement about Lucquin's appointment, emphasizing his strategic vision and operational leadership as key factors in advancing the company's mission. "His commitment to medical innovation makes him the ideal person to guide Okomera into its next stage of growth and achievement," Eglen stated.

Upon taking office, Lucquin shared his enthusiasm for the future of Okomera. He expressed confidence in the company’s potential to significantly influence cancer research and improve global health outcomes through innovative technologies. "Okomera stands at a pivotal moment, built on a solid foundation and driven by a mission to push forward global cancer research," he commented. "I am eager to collaborate with the dedicated Okomera team to build on past successes, strengthen partnerships, and accelerate the development of groundbreaking solutions for researchers worldwide."

Under Lucquin’s leadership, Okomera reaffirms its commitment to pioneering advancements in cancer research, leveraging cutting-edge technologies that integrate microfluidics, cellular biology, and artificial intelligence. The company focuses on developing organoid screening platforms that empower researchers to expedite discoveries and devise more effective treatments for cancer.

As Okomera prepares for this new chapter, the scientific community anticipates further innovations that will emerge under Lucquin's guidance. The company remains steadfast in its goal to support researchers in the relentless fight against cancer.

About Okomera

Okomera is at the forefront of transforming oncology research through state-of-the-art technologies and innovative approaches. By uniting advanced techniques with a clear mission, Okomera aims to reshape the narrative around cancer treatment and improve patient outcomes across the globe.